• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Rituximab noninferior to conventional therapy in ANCA-associated vasculitis: RAVE Trial

byAkira Shishido
February 14, 2014
in Chronic Disease
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD/Rituximab (Rituxan, MabThera)

1. At 18 months, patients with ANCA-associated vasculitis treated with one course of rituximab had similar outcomes in terms of inducing remission when compared to patients treated with conventional continuous immunosuppression therapy.

2. The overall rate of adverse events was similar between both groups; however, patients treated with rituximab had lower incidences of leucopenia and pneumonia. 

Evidence Rating Level: 1 (Excellent) 

Study Rundown:  Granulomatosis with polyangiitis (GPA, formerly Wegener’s) and microscopic polyangiitis (MPA) are systemic vasulidites that are caused by antineutrophil cytoplasmic antibodies (ANCA).  They both can cause renal and pulmonary damage, and are nearly indistinguishable clinically.  Traditionally, patients with these diseases are treated with toxic immunosuppression therapy involving cyclophosphamide and azathioprine.  Recently, the monoclonal anti-B-cell antibody rituximab has been shown to be successful as a treatment for ANCA-associated vasculidites, but its long term efficacy was not known.  This study suggests that patients with severe ANCA-associated vasculitis treated with rituximab had similar outcomes at 18 months when compared to patients treated with conventional therapy.  Even though the results suggest a significantly higher rate of remission among patients who received rituximab, the data did not meet criteria to show superiority, only noninferiority.  While the overall rate of adverse events was similar between the groups, patients treated with rituximab appeared to have lower rates of leucopenia and pneumonia.  The results are not generalizable to patients with vasculidites severe enough to cause advanced renal disease or require ventilatory support, as such patients were excluded from the study.

Click to read the study in NEJM

Relevant Reading: Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis

RELATED REPORTS

ACKR1 variant increases risk of azathioprine-related hematopoietic toxicity

#VisualAbstract: Adding four doses of rituximab did not significantly improve event-free survival over standard of care in acute lymphoblastic leukaemia

#VisualAbstract: Immunocompromised individuals may be at an increased risk of metastses with cutaneous squamous cell carcinomas

In-Depth [randomized double-blind non-inferiority study]: This study examined the outcomes of patients with severe ANCA-associated vasculidites treated with rituximab or conventional therapy for 18 months.  The authors enrolled a total of 197 patients with positive serum assays for either proteinase 3-ANCA or myeloperoxidase-ANCA with severe disease, which was defined as vital-organ involvement that posed an immediate threat to the function of the organ or the patient’s life.  They used the Birmingham Vasculitis Activity Score for Wegener’s Granulomatosis to grade patients on their level of disease activity.  The authors randomized 99 patients to receive rituximab + placebo and 98 to receive conventional therapy consisting of cyclophosphamide and azathioprine.  Both treatment groups received an identical steroid taper that ceased after 5.5 months.  Follow up at 12 and 18 months compared the percentage of patients who had a BVAS/WG score of 0, had completed the steroid taper and had no relapse or treatment failure.

A total of 124 patients completed the 18 month follow up.  64% of patients who received rituximab had achieved remission at 6 months, and 39% maintained remission at 18 months; 53% of patients on conventional therapy achieved remission at 6 months of which 33% maintained remission at 18 months (P<0.001).  Additionally, patients receiving rituximab had fewer episodes of leucopenia and fewer episodes of pneumonia compared to those who received cyclophosphamide-azathioprine.

More from this author: Pneumocystis linked to sudden infant deaths, Continuous infusion of beta-lactams may be superior to bolus therapy, Novel antiviral drug reduces influenza viral load, Three months of antibiotics appear to effectively treat early-onset spinal implant infections 

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Tags: ANCAazathioprinecyclophosphamideGranulomatosis with polyangiitisimmunosuppressionMabTheraRAVE TrialRituxanrituximabvasculitisWegener’s
Previous Post

MERS remains poorly understood, deadly

Next Post

Soaring rates of peripheral artery disease, now over 200 million cases worldwide

RelatedReports

Nearly Half of All Pediatric Buprenorphine Exposures Result in Hospitalization
Chronic Disease

ACKR1 variant increases risk of azathioprine-related hematopoietic toxicity

June 30, 2022
#VisualAbstract: Adding four doses of rituximab did not significantly improve event-free survival over standard of care in acute lymphoblastic leukaemia
StudyGraphics

#VisualAbstract: Adding four doses of rituximab did not significantly improve event-free survival over standard of care in acute lymphoblastic leukaemia

April 8, 2022
#VisualAbstract: Immunocompromised individuals may be at an increased risk of metastses with cutaneous squamous cell carcinomas
StudyGraphics

#VisualAbstract: Immunocompromised individuals may be at an increased risk of metastses with cutaneous squamous cell carcinomas

March 22, 2022
Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial
Oncology

Biosimilar drugs undergo rigorous clinical testing and yield comparable outcomes to biologics

February 22, 2022
Next Post
Soaring rates of peripheral artery disease, now over 200 million cases worldwide

Soaring rates of peripheral artery disease, now over 200 million cases worldwide

Mortality after trauma increasingly due to preexisting conditions

Mortality after trauma increasingly due to preexisting conditions

Propofol appears safe and effective in procedural sedation for cardioversion

Propofol appears safe and effective in procedural sedation for cardioversion

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Early exposure to allergenic foods may reduce incidence of long-term food allergy
  • Risk of post-vitrectomy endophthalmitis may have increased during the COVID-19 pandemic
  • Bosniak classification system differentiates benign renal cysts from cystic carcinoma [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.